{"denoms":[{"counts":[{"groupId":"BG000","value":"373"},{"groupId":"BG001","value":"376"},{"groupId":"BG002","value":"749"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\\^2 IV Q3W and 5-FU 800 mg/m\\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.","id":"BG000","title":"Pembrolizumab + SOC"},{"description":"Participants received placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\\^2 IV Q3W and 5-FU 800 mg/m\\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.","id":"BG001","title":"Placebo + SOC"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.8","value":"62.8"},{"groupId":"BG001","spread":"9.2","value":"62.0"},{"groupId":"BG002","spread":"9.5","value":"62.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"124"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"306"},{"groupId":"BG001","value":"319"},{"groupId":"BG002","value":"625"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"99"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"296"},{"groupId":"BG002","value":"611"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"39"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"21"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"400"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"139"},{"groupId":"BG002","value":"278"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"14"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"29"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"196"},{"groupId":"BG001","value":"197"},{"groupId":"BG002","value":"393"}],"title":"Asia"},{"measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"356"}],"title":"Rest of World"}]}],"description":"Participants were stratified according to Geographic Region of enrolling site (Asia versus Rest of World)","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"201"}],"title":"Adenocarcinoma"},{"measurements":[{"groupId":"BG000","value":"274"},{"groupId":"BG001","value":"274"},{"groupId":"BG002","value":"548"}],"title":"Squamous Cell Carcinoma"}]}],"description":"Participants were stratified according to baseline Histology (adenocarcinoma versus squamous cell carcinoma)","paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"299"}],"title":"ECOG PS 0"},{"measurements":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"448"}],"title":"ECOG PS 1"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"ECOG PS 2"}]}],"description":"ECOG PS 0 = Fully active, able to carry on all pre-disease performance without restriction), ECOG PS 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, ECOG PS 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours. Participants were stratified according to baseline ECOG PS (0 versus 1).","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Group Performance Status (ECOG PS)","unitOfMeasure":"Participants"}]}